| |
|
|
Session 70
Poster Presentations Resistance Testing: Methodology and Clinical Applications Tuesday 1:30 - 3:30 pm Hall A |
| 580 | Use of Uracil N-glycosylase Negative E. Coli to Clone dUTP-containing HIV-1 DNA Generated Using a Commercial HIV-1 Genotyping System S. H. Eshleman*1, D. Jones1, O. Petrauskene2, J. B. Jackson1 1Johns Hopkins Med Inst, Baltimore, MD and 2Applied Biosystems, Foster City, CA |
| 581 | Evaluation of a Rapid Phenotypic Assay for Nevirapine Resistance in Ugandan Women who Received Single-dose NVP Prophylaxis in HIVNET 012 S. H. Eshleman*1, R. Cheingsong2, G. Garcia-Lerma2, E. Paxinos3, J. B. Jackson1, W. Heneine2 1Johns Hopkins Med Inst, Baltimore, MD; 2CDC, Atlanta, GA; and 3ViroLogic, San Francisco, CA |
| 582 | Performance of Celera Diagnostics ViroSeq HIV-1 Genotyping System on Genetically Diverse HIV-1 Strains N. Marlowe*1, P. Swanson2, B. Drews1, J. Hackett2 1Celera Diagnostics, Alameda, CA and 2Abbott Labs, Abbott Park, IL |
| 583 | New Real-time RT-PCR Assay Quantifies K103N NNRTI-resistant Variant at a Frequency as Low as 0.01% S. Palmer1, V. Boltz*1, F. Maldarelli1, E. Halvas2, J. Mellors2, J. Coffin1 1HIV Drug Resistance Prgm, NCI, NIH, Frederick, MD and 2Univ of Pittsburgh, PA |
| 584 | Variability in Quality Assessment Data from Replicate Genotyping of Clinical Samples D. Huang*1, D. Brambilla2, A. Ouma1, S. Granger2, N. Coppinger2, J. Bremer1 1Rush Med Coll, Chicago, IL and 2New England Res Inst Inc, Watertown, MA |
| 585 | Distribution of Phenotypic Drug Susceptibility Among More than 2,000 Wild-type Viruses N.T. Parkin*, N. Hellmann, J. Whitcomb, L. Kiss, C. Chappey, C.J. Petropoulos ViroLogic, San Francisco, CA |
| 586 | Prediction of NRTI Options by Linking Reverse Transcriptase Genotype to Phenotypic Breakpoints ER Lanier*1, D Irlbeck1, L Ross1, P Gerondelis1, M Underwood1, N Parkin2, C Chappey2, M St Clair1 1GlaxoSmithKline, Research Triangle Park, NC and 2ViroLogic, San Francisco, CA |
| 587 | Predicting Phenotypic Susceptibility Levels of HIV Reverse Transcriptase and Protease from Genotype using Tree Modeling Methods K. Tsai*1, G. Heilek-Snyder1, F. Evalle1, C. Su1, B. Chinn1, S. Chiu1, P. Sista2, N. Cammack1 1Roche BioSci, Palo Alto, CA and 2Trimeris, Durham, NC |
| 588 | Impact of Shorter Sequence Length on HIV-1 Drug Resistance Analysis Outcome and Clade Assignment via Virtual Phenotype P. Lecocq *1, M. Van Houtte 1, J. Veldeman 1, L. Bacheler 2 1VIRCO BVBA, Mechelen, Belgium and 2VIRCO USA, Durham, NC |
| 589 | Combining Genotype Groups and Recursive Partitioning: An Application to HIV-1 Genetics Data A. Foulkes*1, V. Degruttola2, K. Hertogs3, L. Bachelor4 1Univ of Pennsylvania Sch of Med, Philadelphia; 2Harvard Sch of Public Hlth, Boston, MA; 3Tibotec-Virco, Mechelen, Belgium; and 4Vircolab, Inc, Durham, NC |
| 590 | Nucleotide Incorporation during First-round RT PCR as the Main Contributor of Sequence-based HIV Genotyping Variability B. Sattha, B. Wynhoven, P.R. Harrigan, M.V. O'Shaughnessy, R. Galli* British Columbia Ctr for Excellence in HIV/AIDS, Vancouver, Canada |
| 591 | Blinded, Multi-center Comparison of the Sensitivity of Different Technologies to Detect and Quantify Minor Drug-resistant HIV-1 Variants E. Halvas*1, G. Androvandi2, P. Balfe3, I. Beck4, V. Boltz5, L. Frankel4, M. Kearney5, A. Kovacs6, K. Metzner7, D. Nissley5, M. Nowicki6, R. Ziermann8, Y. Zhao9, C. Jennings11, J. Mellors1 1Univ of Pittsburgh, PA; 2Univ of Alabama at Birmingham; 3Columbia Univ, New York, NY; 4Univ of Washington, Seattle; 5Natl Cancer Inst, Frederick, MD; 6Univ of Southern California, Los Angeles; 7Univ of Erlangen-Nurenberg, Erlangen, Germany; 8Bayer Diagnostics, Emerysville, CA; 9Children's Mem Hosp, Chicago, IL; 10Virology Quality Assurance, Chicago, IL; and 11Rush Med Coll, Chicago, IL |
| 592 | CREST-A Randomized Comparison of Genotype and Genotype Plus Virtual Phenotype (VircoGen II) S. Emery*1, G. Hales1, C. Birch2, S. Crowe4, J. Hoy5,6, C. Workman7, A. Kellerher1, A. Rinehart8, P. McKenna8, M. Law1 1Univ of New South Wales, Sydney, Australia; 2Victorian Infectious Disease Reference Lab, Melbourne, Australia; 3Burnet Inst, Melbourne, Australia; 4Alfred Hosp, Melbourne, Australia; 5Monash Univ, Melbourne, Australia; 6AIDS Res Initiative, Sydney, Australia; 7Tibotec-Virco USA, Durham, NC; and 8Tibotec-Virco BVBA, Mechelen, Belgium |